PTGS2 and cancer: Regarding COX-2 final score, 33/77 (42.9%) tumors did not present any COX-2 expression, corresponding to 28/39 (71.8%) benign and 5/38 (13.2%) malignant tumors; 32/77 (41.6%) tumors presented low expression, corresponding to 8/39 (20.5%) benign and 24/38 (63.2%) malignant tumors; 12/77 (15.6%) presented high expression, corresponding to 3/39 (7.7%) benign and 9/38 (23.7%) malignant tumors.